<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294200</url>
  </required_header>
  <id_info>
    <org_study_id>CIP 2101-01</org_study_id>
    <nct_id>NCT03294200</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System</brief_title>
  <official_title>Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4Tech Cardio Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4Tech Cardio Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to generate safety and performance data for the 4Tech TriCinch
      Coil System in symptomatic patients suffering from significant functional tricuspid
      regurgitation with annular dilatation.

      The TriCinch Coil System is a percutaneous catheter-based medical device for tricuspid valve
      repair.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality of the Per Protocol cohort at 30 days post procedure.</measure>
    <time_frame>30 days post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of individual adverse events related to the system or procedure.</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic changes compared to Baseline by means of echocardiographic semi-quantitative and quantitative measures</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional changes as compared to Baseline for New York Heart Association (NYHA) classification</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Heart Failure event post-procedure defined as a heart failure hospitalization or a heart failure hospitalization equivalent</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance (Six Minute Walk Test)</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life evaluation (Kansas City Cardiomyopathy Questionnaire).</measure>
    <time_frame>30 days, three (3), six (6), twelve (12) and twenty-four (24) months post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Tricinch Coil System treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TriCinch Coil System implantation</intervention_name>
    <description>Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.</description>
    <arm_group_label>Tricinch Coil System treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Moderate to severe functional tricuspid regurgitation (TR) defined as: TR severity 2+
             to 4+ (according to semi-quantitative echocardiographic color flow doppler
             evaluation); and Annular diameter ≥ 40 mm confirmed by echocardiography

          2. ≥ 18 years old

          3. Subject has read and signed the informed consent prior to study related procedures.

          4. Willing and able to comply with all required follow-up evaluations and assessments.

          5. The 'Heart Team' assessment recommends TriCinch Coil Implantation

          6. New York Heart Associate Classification ≥ II.

          7. Left Ventricular Ejection Fraction ≥ 30%.

          8. Heart failure symptoms (such as fluid retention and severe oedema, liver stasis)
             despite on optimized medical therapy by the local heart team; at minimum subject on
             diuretic use

          9. Subject has suitable anatomy for investigational device implantation as per imaging
             requirements

        Exclusion Criteria:

          1. Currently participating in another investigational drug or device study.

          2. Subject with Systolic pulmonary arterial pressure (sPAP) &gt; 60mmHg as measured by
             Transthoracic Echocardiography (TTE)

          3. Subject requiring another cardiac procedure in the framework of the index procedure;
             subject requiring a percutaneous procedure within 30 days before or after the
             procedure or a cardiac surgical procedure within 3 months before or after the
             procedure

          4. Moderate or Severe tricuspid valve stenosis (defined as a mean gradient ≥5 mmHg at
             normal heart rate)

          5. Aortic, mitral and/or pulmonic valve stenosis and/or regurgitation more than or equal
             to moderate

          6. Mitral valve stenosis and/or regurgitation more than moderate

          7. Intra-cardiac thrombus, mass or vegetation requiring active treatment.

          8. Implanted inferior vena cava (IVC) filter.

          9. Prior tricuspid repair or tricuspid replacement

         10. Known allergy to contrast media, silicone, PET, Co-Cr, stainless steel or nitinol that
             cannot be adequately pre-medicated

         11. History of cardiac transplantation

         12. Contraindication to Transthoracic/Transoesophageal Echocardiography (TTE/TOE).

         13. Endocarditis or severe infection within 12 months of scheduled implant procedure

         14. Myocardial Infarction (MI) or known unstable angina within the 30 days prior to the
             index procedure

         15. Cerebro Vascular Accident within the previous 6 months

         16. Hemodynamic instability or on IV inotropes

         17. Contraindication to anticoagulant therapy and antiplatelet therapy

         18. Bleeding disorders or hypercoagulable condition (at risk of blood clots)

         19. Active peptic ulcer or active GI bleeding within 3 months of scheduled implant
             procedure

         20. Severe renal impairment or on dialysis

         21. Life expectancy less than 12 months.

         22. Acute anemia

         23. Chronic Oral Steroid Use ≥ 6 months

         24. Pregnant or lactating female of childbearing potential with a positive pregnancy test
             24 hours before any study-related radiation exposure

         25. Pulmonary embolism within the last 6 months

         26. Tricuspid Valve Tethering distance &gt; 10 mm

         27. Presence of trans-tricuspid pacemaker or defibrillator leads which are determined as
             immobile or interfering with the procedure, as evaluated by echocardiography.

         28. Contra-indicated for blood transfusion or refuses transfusion

         29. Patient undergoing emergency treatment

         30. Patient without appropriate venous access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hardip Thakerar</last_name>
    <phone>+44 796 104 9197</phone>
    <email>hardip.thakerar@4tech.ie</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Monash Heart</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Van Der Heyden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Institut Coeur Poumon - CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Tchetche, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Horst Sievert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Van Mieghem, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brighton &amp; Sussex University Hospitals - Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hildick-Smith, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Blackman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Byrne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX9 3DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Banning, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

